Lung cancer screening: yes or no during the COVID pandemic?

  • Mazzone PJ & al.
  • Chest
  • 22 Apr 2020

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A team of international experts has developed 12 consensus statements offering guidance for lung cancer screening (LCS) and lung nodule evaluation during the COVID-19 pandemic.

Why this matters

  • The current global pandemic places a strain on resource availability and increases patient risks.

Key recommendations

  • Delay baseline and annual LCS.
  • Delay by 3-6 months the evaluation of low-risk nodules including those measuring
  • Delay follow-up screening by 3-6 months in patients with nodules ≥8 mm in average diameter (or a Lung-RADS category 4 screening-detected lung nodule) and
  • Delay follow-up screening by 3-6 months in patients with part-solid lung nodule with the solid component ≥8 mm in diameter.
  • PET scan and/or nonsurgical biopsy is recommended for patients with solid nodules ≥8 mm (or a Lung-RADS category 4 screening-detected lung nodule) and 65%-85% malignancy probability.
  • Develop treatment plan without further screening for patients with solid nodules ≥8 mm (or a Lung-RADS category 4 screening-detected lung nodule) and malignancy probability >85%.
  • Treatment may be delayed for stage I NSCLC in some cases.